(Circulation. 1996;94:3184-3189.)
© 1996 American Heart Association, Inc.
Articles |
Hemodynamic and Renal Excretory Effects of Human Brain Natriuretic Peptide Infusion in Patients With Congestive Heart Failure
A Double-Blind, Placebo-Controlled, Randomized Crossover Trial
Columbia Presbyterian Medical Center, Department of Medicine, Divisions of Circulatory Physiology and Cardiology, Columbia University College of Physicians and Surgeons, New York, NY, and the Columbia University School of Public Health, Division of Biostatistics, New York, NY.
Correspondence to Stuart D. Katz, MD, Columbia Presbyterian Medical Center, Division of Circulatory Physiology, Room MHB5-435, 177 Fort Washington Ave, New York, NY 10032. E-mail sdk8@columbia.edu.
Background The pharmacological effects of infusion of human brain natriuretic peptide (hBNP) in patients with severe congestive heart failure have not been characterized previously.
Methods and Results Twenty patients with severe congestive heart failure were randomized in a double-blind, placebo-controlled, crossover trial to receive incremental 90-minute infusions of hBNP (0.003, 0.01, 0.03, and 0.1 µg/kg per minute) or placebo on 2 consecutive days. At the highest completed dose of the hBNP, mean pulmonary artery pressure decreased from 38.3±1.6 to 25.9±1.7 mm Hg; mean pulmonary capillary wedge pressure decreased from 25.1±1.1 to 13.2±1.3 mm Hg; mean right atrial pressure decreased from 10.9±1 to 4.8±1.0 mm Hg; mean arterial pressure decreased from 85.2±2.0 to 74.9±1.7 mm Hg; and cardiac index increased from 2.0±0.1 to 2.5±0.1 L/min per square meter (all P<.01 versus placebo). Urine volume and urine sodium excretion increased significantly during hBNP infusion when compared with placebo infusion (90±38 versus 67±27 mL/h and 2.6±2.4 versus 1.4±1.2 mEq/h, respectively, both P<.05 versus placebo), whereas creatinine clearance and urinary potassium excretion did not change.
Conclusions Infusion of incremental doses of hBNP is associated with favorable hemodynamic and natriuretic effects in patients with severe congestive heart failure. (Circulation. 1996;94:3184-3189.)
Key Words: heart failure • natriuretic peptides • hemodynamics • pharmacology • drugs
This article has been cited by other articles:
 |
|
 |
|
  I. George, B. Morrow, K. Xu, G.-H. Yi, J. Holmes, E. X. Wu, Z. Li, A. A. Protter, M. C. Oz, and J. Wang Prolonged effects of B-type natriuretic peptide infusion on cardiac remodeling after sustained myocardial injury Am J Physiol Heart Circ Physiol, August 1, 2009; 297(2): H708 - H717. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Boerrigter, L. C. Costello-Boerrigter, G. J. Harty, B. K. Huntley, A. Cataliotti, H. Lapp, and J. C. Burnett Jr. B-type natriuretic peptide 8-32, which is produced from mature BNP 1-32 by the metalloprotease meprin A, has reduced bioactivity Am J Physiol Regulatory Integrative Comp Physiol, June 1, 2009; 296(6): R1744 - R1750. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Simsic, W. T. Mahle, A. Cuadrado, P. M. Kirshbom, and K. O. Maher Hemodynamic Effects and Safety of Nesiritide in Neonates with Heart Failure J Intensive Care Med, November 1, 2008; 23(6): 389 - 395. [Abstract] [PDF]
|
|
|
|
|
|
A. Ryan, D. A. Rosen, and J. D. Tobias Preliminary Experience With Nesiritide in Pediatric Patients Less Than 12 Months of Age J Intensive Care Med, September 1, 2008; 23(5): 321 - 328. [Abstract] [PDF]
|
|
|
|
 |
|
 J. C. Burnett Jr and J. Korinek The Tumultuous Journey of Nesiritide: Past, Present, and Future Circ Heart Fail, May 1, 2008; 1(1): 6 - 8. [Full Text] [PDF]
|
|
|
|
 |
|
 P. Symeonides, S. Koulouris, E. Vratsista, K. Triantafyllou, G. Ioannidis, N. Thalassinos, and D. Katritsis Both ramipril and telmisartan reverse indices of early diabetic cardiomyopathy: A comparative study Eur J Echocardiogr, December 1, 2007; 8(6): 480 - 486. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. M. Witteles, D. Kao, D. Christopherson, K. Matsuda, R. H. Vagelos, D. Schreiber, and M. B. Fowler Impact of Nesiritide on Renal Function in Patients With Acute Decompensated Heart Failure and Pre-Existing Renal Dysfunction: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial J. Am. Coll. Cardiol., November 6, 2007; 50(19): 1835 - 1840. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. L Chow, J. T Peng, M. P Okamoto, and J T. Heywood Effect of Nesiritide Infusion Duration on Renal Function in Acutely Decompensated Heart Failure Patients Ann. Pharmacother., April 1, 2007; 41(4): 556 - 561. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Belenkie Nesiritide Administration in Patients With Left Ventricular Dysfunction Undergoing Coronary Artery Bypass Surgery J. Am. Coll. Cardiol., February 13, 2007; 49(6): 727 - 728. [Full Text] [PDF]
|
|
|
|
|
|
R. M. Mentzer Jr, M. C. Oz, R. N. Sladen, A. H. Graeve, R. F. Hebeler Jr, J. M. Luber Jr, N. G. Smedira, and on behalf of the NAPA Investigators Effects of Perioperative Nesiritide in Patients With Left Ventricular Dysfunction Undergoing Cardiac Surgery: The NAPA Trial J. Am. Coll. Cardiol., February 13, 2007; 49(6): 716 - 726. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Belluardo, A. Cataliotti, L. Bonaiuto, E. Giuffre, E. Maugeri, P. Noto, G. Orlando, G. Raspa, B. Piazza, L. Babuin, et al. Lack of activation of molecular forms of the BNP system in human grade 1 hypertension and relationship to cardiac hypertrophy Am J Physiol Heart Circ Physiol, October 1, 2006; 291(4): H1529 - H1535. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. H. Chen and J. C. Burnett Jr Clinical application of the natriuretic peptides in heart failure Eur. Heart J. Suppl., September 1, 2006; 8(suppl_E): E18 - E25. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. G. Riter, M. M. Redfield, J. C. Burnett, and H. H. Chen Nonhypotensive Low-Dose Nesiritide Has Differential Renal Effects Compared With Standard-Dose Nesiritide in Patients With Acute Decompensated Heart Failure and Renal Dysfunction J. Am. Coll. Cardiol., June 6, 2006; 47(11): 2334 - 2335. [Full Text] [PDF]
|
|
|
|
 |
|
 S. J. Roth, I. Adatia, G. D. Pearson, and and Members of the Cardiology Group Summary proceedings from the cardiology group on postoperative cardiac dysfunction. Pediatrics, March 1, 2006; 117(3 Pt 2): S40 - S46. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Simsic, M. Scheurer, J. D. Tobias, J. Berkenbosch, W. Schechter, F. Madera, S. Weinstein, and R. E. Michler Perioperative Effects and Safety of Nesiritide Following Cardiac Surgery in Children J Intensive Care Med, January 1, 2006; 21(1): 22 - 26. [Abstract] [PDF]
|
|
|
|
 |
|
 J. B. Bauer and M. A. Randazzo Nesiritide for outpatient treatment of heart failure Am. J. Health Syst. Pharm., December 15, 2005; 62(24): 2639 - 2642. [Full Text] [PDF]
|
|
|
|
|
|
W. T. Abraham, K. F. Adams, G. C. Fonarow, M. R. Costanzo, R. L. Berkowitz, T. H. LeJemtel, M. L. Cheng, J. Wynne, the ADHERE Scientific Advisory Committee Investiga, and and the ADHERE Study Group In-Hospital Mortality in Patients With Acute Decompensated Heart Failure Requiring Intravenous Vasoactive Medications: An Analysis From the Acute Decompensated Heart Failure National Registry (ADHERE) J. Am. Coll. Cardiol., July 5, 2005; 46(1): 57 - 64. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. J. Campbell, M. Woodward, J. P. Chalmers, S. A. Colman, A. J. Jenkins, B. E. Kemp, B. C. Neal, A. Patel, and S. W. MacMahon Prediction of Myocardial Infarction by N-Terminal-Pro-B-Type Natriuretic Peptide, C-Reactive Protein, and Renin in Subjects With Cerebrovascular Disease Circulation, July 5, 2005; 112(1): 110 - 116. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. D. Sackner-Bernstein, M. Kowalski, M. Fox, and K. Aaronson Short-term Risk of Death After Treatment With Nesiritide for Decompensated Heart Failure: A Pooled Analysis of Randomized Controlled Trials JAMA, April 20, 2005; 293(15): 1900 - 1905. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
U. Elkayam, D. J. Wang, T. C. Dowling, D. Meadows, T. Ayala, J. Marshall, S. Minshall, N. Greenberg, E. Thattassery, M. L. Fisher, et al. Letter Regarding Article by Wang et al, "Nesiritide Does Not Improve Renal Function in Patients With Chronic Heart Failure and Worsening Serum Creatinine" * Response Circulation, April 12, 2005; 111(14): e182 - e183. [Full Text] [PDF]
|
|
|
|
|
|
J. C. Burnett Nesiritide: new hope for acute heart failure syndromes? Eur. Heart J. Suppl., April 1, 2005; 7(suppl_B): B25 - B30. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. L. Smull and U. P. Jorde Concomitant use of nesiritide and milrinone in decompensated congestive heart failure Am. J. Health Syst. Pharm., February 1, 2005; 62(3): 291 - 295. [Full Text] [PDF]
|
|
|
|
|
|
M. Sheikh-Taha Intermittent nesiritide therapy in outpatients with chronic heart failure Am. J. Health Syst. Pharm., January 15, 2005; 62(2): 196 - 198. [Full Text] [PDF]
|
|
|
|
 |
|
 N. M. Albert, C. A. Eastwood, and M. L. Edwards Evidence-Based Practice for Acute Decompensated Heart Failure Crit. Care Nurse, December 1, 2004; 24(6): 14 - 29. [Full Text] [PDF]
|
|
|
|
 |
|
 L. E. Samuels, E. C. Holmes, and L. Letwin Nesiritide as an adjunctive therapy in adult patients with heart failure undergoing high-risk cardiac surgery J. Thorac. Cardiovasc. Surg., October 1, 2004; 128(4): 627 - 629. [Full Text] [PDF]
|
|
|
|
|
|
M. G. Shlipak and B. M. Massie The Clinical Challenge of Cardiorenal Syndrome Circulation, September 21, 2004; 110(12): 1514 - 1517. [Full Text] [PDF]
|
|
|
|
|
|
D. J. Wang, T. C. Dowling, D. Meadows, T. Ayala, J. Marshall, S. Minshall, N. Greenberg, E. Thattassery, M. L. Fisher, K. Rao, et al. Nesiritide Does Not Improve Renal Function in Patients With Chronic Heart Failure and Worsening Serum Creatinine Circulation, September 21, 2004; 110(12): 1620 - 1625. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Chang, W. A. Elatre, and J. T. Heywood Effect of Nesiritide on Length of Hospital Stay in Patients with Decompensated Heart Failure Journal of Cardiovascular Pharmacology and Therapeutics, July 1, 2004; 9(3): 173 - 177. [Abstract] [PDF]
|
|
|
|
 |
|
 D. C. Kurian, I. J. Wagner, and M. Klapholz Nesiritide in Pulmonary Hypertension Chest, July 1, 2004; 126(1): 302 - 305. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Cataliotti, G. Boerrigter, L. C. Costello-Boerrigter, J. A. Schirger, T. Tsuruda, D. M. Heublein, H. H. Chen, L. S. Malatino, and J. C. Burnett Jr Brain Natriuretic Peptide Enhances Renal Actions of Furosemide and Suppresses Furosemide-Induced Aldosterone Activation in Experimental Heart Failure Circulation, April 6, 2004; 109(13): 1680 - 1685. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Butler, C. Emerman, W. F. Peacock, V. S. Mathur, and J. B. Young The efficacy and safety of B-type natriuretic peptide (nesiritide) in patients with renal insufficiency and acutely decompensated congestive heart failure Nephrol. Dial. Transplant., February 1, 2004; 19(2): 391 - 399. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. de Denus, C. Pharand, and D. R. Williamson Brain Natriuretic Peptide in the Management of Heart Failure: The Versatile Neurohormone Chest, February 1, 2004; 125(2): 652 - 668. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. W. Dorn II and J. D. Molkentin Manipulating Cardiac Contractility in Heart Failure: Data From Mice and Men Circulation, January 20, 2004; 109(2): 150 - 158. [Full Text] [PDF]
|
|
|
|
 |
|
 A. Prahash and T. Lynch B-Type Natriuretic Peptide: A Diagnostic, Prognostic, and Therapeutic Tool in Heart Failure Am. J. Crit. Care., January 1, 2004; 13(1): 46 - 53. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. I. McFarlane, N. Winer, and J. R. Sowers Role of the Natriuretic Peptide System in Cardiorenal Protection Arch Intern Med, December 8, 2003; 163(22): 2696 - 2704. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Vichiendilokkul, A. Tran, and E. Racine Nesiritide: A Novel Approach for Acute Heart Failure Ann. Pharmacother., February 1, 2003; 37(2): 247 - 258. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
U. Elkayam, M. W. Akhter, P. Tummala, S. Khan, and H. Singh Nesiritide: A New Drug for the Treatment of Decompensated Heart Failure Journal of Cardiovascular Pharmacology and Therapeutics, September 1, 2002; 7(3): 181 - 194. [Abstract] [PDF]
|
|
|
|
 |
|
 M. A. Militello Role of Nesiritide in Decompensated Heart Failure Journal of Pharmacy Practice, August 1, 2002; 15(4): 326 - 333. [Abstract] [PDF]
|
|
|
|
|
|
M. A. Silver, D. P. Horton, J. K. Ghali, and U. Elkayam Effect of nesiritide versus dobutamine on short-term outcomes in the treatment of patients with acutely decompensated heart failure J. Am. Coll. Cardiol., March 6, 2002; 39(5): 798 - 803. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.o. Koglin, S. Pehlivanli, M. Schwaiblmair, M. Vogeser, P. Cremer, and W. vonScheidt Role of brain natriuretic peptide in risk stratification of patients with congestive heart failure J. Am. Coll. Cardiol., December 1, 2001; 38(7): 1934 - 1941. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. N. Chan and S. J. Hurel Brain Natriuretic Peptide as a Potential Marker of Diastolic Dysfunction in Type 2 Diabetes Diabetes Care, November 1, 2001; 24(11): 2019 - 2020. [Full Text] [PDF]
|
|
|
|
 |
|
 D. L Vesely Atrial natriuretic peptides in pathophysiological diseases Cardiovasc Res, September 1, 2001; 51(4): 647 - 658. [Full Text] [PDF]
|
|
|
|
|
|
G. A. Sagnella Atrial natriuretic peptide mimetics and vasopeptidase inhibitors Cardiovasc Res, August 15, 2001; 51(3): 416 - 428. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Boomsma and A. H. van den Meiracker Plasma A- and B-type natriuretic peptides: physiology, methodology and clinical use Cardiovasc Res, August 15, 2001; 51(3): 442 - 449. [Full Text] [PDF]
|
|
|
|
|
|
W.-G. Forssmann, M. Meyer, and K. Forssmann The renal urodilatin system: clinical implications Cardiovasc Res, August 15, 2001; 51(3): 450 - 462. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. R Kalra, S. D Anker, and A. J.S Coats Water and sodium regulation in chronic heart failure: the role of natriuretic peptides and vasopressin Cardiovasc Res, August 15, 2001; 51(3): 495 - 509. [Full Text] [PDF]
|
|
|
|
|
|
H. Peter Brunner-La Rocca, W. Kiowski, D. Ramsay, and G. Sutsch Therapeutic benefits of increasing natriuretic peptide levels Cardiovasc Res, August 15, 2001; 51(3): 510 - 520. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. P. Brunner-La Rocca, D. M. Kaye, R. L. Woods, J. Hastings, and M. D. Esler Effects of intravenous brain natriuretic peptide on regional sympathetic activity in patients with chronic heart failure as compared with healthy control subjects J. Am. Coll. Cardiol., April 1, 2001; 37(5): 1221 - 1227. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. A Sagnella Practical implications of current natriuretic peptide research Journal of Renin-Angiotensin-Aldosterone System, December 1, 2000; 1(4): 304 - 315. [PDF]
|
|
|
|
|
|
H. H. Chen, J. A. Grantham, J. A. Schirger, M. Jougasaki, M. M. Redfield, and J. C. Burnett Jr. Subcutaneous administration of brain natriuretic peptide in experimental heart failure J. Am. Coll. Cardiol., November 1, 2000; 36(5): 1706 - 1712. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Maeda, T. Tsutamoto, A. Wada, N. Mabuchi, M. Hayashi, T. Hisanaga, T. Kamijo, and M. Kinoshita Insufficient secretion of atrial natriuretic peptide at acute phase of myocardial infarction J Appl Physiol, August 1, 2000; 89(2): 458 - 464. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. S. Colucci, U. Elkayam, D. P. Horton, W. T. Abraham, R. C. Bourge, A. D. Johnson, L. E. Wagoner, M. M. Givertz, C.-s. Liang, M. Neibaur, et al. Intravenous Nesiritide, a Natriuretic Peptide, in the Treatment of Decompensated Congestive Heart Failure N. Engl. J. Med., July 27, 2000; 343(4): 246 - 253. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. G. Lainchbury, J. C. Burnett Jr., D. Meyer, and M. M. Redfield Effects of natriuretic peptides on load and myocardial function in normal and heart failure dogs Am J Physiol Heart Circ Physiol, January 1, 2000; 278(1): H33 - H40. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. M. Mills, T. H. LeJemtel, D. P. Horton, C.-s. Liang, R. Lang, M. A. Silver, C. Lui, K. Chatterjee, and on Behalf of the Natrecor Study Group Sustained hemodynamic effects of an infusion of nesiritide (human b-type natriuretic peptide) in heart failure: A randomized, double-blind, placebo-controlled clinical trial J. Am. Coll. Cardiol., July 1, 1999; 34(1): 155 - 162. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. G. Lainchbury, M. G. Nicholls, E. A. Espiner, T. G. Yandle, L. K. Lewis, and A. M. Richards Bioactivity and Interactions of Adrenomedullin and Brain Natriuretic Peptide in Patients With Heart Failure Hypertension, July 1, 1999; 34(1): 70 - 75. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Matsumoto, A. Wada, T. Tsutamoto, T. Omura, H. Yokohama, M. Ohnishi, I. Nakae, M. Takahashi, and M. Kinoshita Vasorelaxing effects of atrial and brain natriuretic peptides on coronary circulation in heart failure Am J Physiol Heart Circ Physiol, June 1, 1999; 276(6): H1935 - H1942. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Almirez and A. A. Protter Clearance of Human Brain Natriuretic Peptide in Rabbits; Effect of the Kidney, the Natriuretic Peptide Clearance Receptor, and Peptidase Activity J. Pharmacol. Exp. Ther., May 1, 1999; 289(2): 976 - 980. [Abstract] [Full Text]
|
|
|
|
|
|
C. Zellner, A. A. Protter, E. Ko, M. R. Pothireddy, T. DeMarco, S. J. Hutchison, T. M. Chou, K. Chatterjee, and K. Sudhir Coronary vasodilator effects of BNP: mechanisms of action in coronary conductance and resistance arteries Am J Physiol Heart Circ Physiol, March 1, 1999; 276(3): H1049 - H1057. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. G. Lainchbury, A. M. Richards, M. G. Nicholls, E. A. Espiner, and T. G. Yandle Brain Natriuretic Peptide and Neutral Endopeptidase Inhibition in Left Ventricular Impairment J. Clin. Endocrinol. Metab., February 1, 1999; 84(2): 723 - 729. [Abstract] [Full Text]
|
|
|
|
|
|
B. M. Y. Cheung and C. R. Kumana Natriuretic Peptides--Relevance in Cardiovascular Disease JAMA, December 16, 1998; 280(23): 1983 - 1984. [Full Text] [PDF]
|
|
|
|
|
|
A. Luchner, J. C. Burnett Jr., M. Jougasaki, H.-W. Hense, G.u. A. J. Riegger, and H. Schunkert Augmentation of the cardiac natriuretic peptides by beta-receptor antagonism: evidence from a population-based study J. Am. Coll. Cardiol., December 1, 1998; 32(7): 1839 - 1844. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. E. Clemens, R. G. Almirez, K. A. Baudouin, R. P. Mischak, E. B. Grossbard, and A. A. Protter Pharmacokinetics and Biological Actions of Subcutaneously Administered Human Brain Natriuretic Peptide J. Pharmacol. Exp. Ther., October 1, 1998; 287(1): 67 - 71. [Abstract] [Full Text]
|
|
|
|
|
|
J. G. Lainchbury, A. M. Richards, M. G. Nicholls, P. J. Hunt, H. Ikram, E. A. Espiner, T. G. Yandle, and E. Begg The Effects of Pathophysiological Increments in Brain Natriuretic Peptide in Left Ventricular Systolic Dysfunction Hypertension, September 1, 1997; 30(3): 398 - 404. [Abstract] [Full Text]
|
|